SUPERIOR ANTI-TUMOR ACTIVITY OF THE MDM2 ANTAGONIST IDASANUTLIN AND THE BCL-2 INHIBITOR VENETOCLAX IN P53 WILD-TYPE ACUTE MYELOID LEUKEMIA MODELS

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

Abstract Background Venetoclax, a small molecule BH3 mimetic which inhibits the anti-apoptotic protein Bcl-2, and idasanutlin, a selective MDM2 antagonist, have both shown activity as single-agent treatments in pre-clinical and clinical studies in acute myeloid leukemia (AML).In this study, we deliver the rationale and molecular basis for the combi

read more


School environment and school injuries

Background: Although injuries at school are an important issue in public health, environmental factors in schools and school yards have seldom been the focus of school injury research.The goal of our investigation was to examine the effect of environmental factors on school Dugouts injuries.Methods: Nine comprehensive Finnish schools registered sch

read more